公开(公告)号：JP2006206597A

公开(公告)日：2006-08-10

申请号：JP2006052376

申请日：2006-02-28

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： STUK TIMOTHY L ,  KERDESKY FRANCIS A J ,  LIJEWSKI LINDA M ,  NORBECK DANIEL W ,  SCARPETTI DAVID ,  TIEN JIEN-HEH J ,  ALLEN MICHAEL S ,  LANGRIDGE DENTON C ,  MELCHER LAURA ,  RENO DANIEL S ,  SHAM HING LEUNG ,  ZHAO CHEN ,  HAIGHT ANTHONY R ,  LEANNA M ROBERT ,  MORTON HOWARD E ,  ROBBINS TIMOTHY A ,  SOWIN THOMAS J

IPC: C07C215/28 ,  C07B61/00 ,  C07C213/00 ,  C07C225/14 ,  C07C225/16 ,  C07C227/18 ,  C07C229/36 ,  C07C231/12 ,  C07C233/35 ,  C07C251/38 ,  C07C251/40 ,  C07C255/27 ,  C07C255/42 ,  C07C269/06 ,  C07C271/20 ,  C07D209/44 ,  C07D221/14

CPC classification number: C07D221/14 ,  C07B2200/07 ,  C07C213/00 ,  C07C215/28 ,  C07C225/16 ,  C07C251/40 ,  C07C255/42 ,  C07C269/06 ,  C07C271/20 ,  C07D209/44 ,  C07C215/08

Abstract: PROBLEM TO BE SOLVED: To provide a substituted 2,5-diamino-3-hydroxyhexane useful for producing HIV protease inhibitors, and to provide a method for producing the compound.
SOLUTION: The substituted 2,5-diamino-3-hydroxyhexane useful for producing HIV protease inhibitors is represented by general formula I.
COPYRIGHT: (C)2006,JPO&NCIPI

Abstract translation: 待解决的问题：提供可用于产生HIV蛋白酶抑制剂的取代的2,5-二氨基-3-羟基己烷，并提供一种生产该化合物的方法。 解决方案：用于生产HIV蛋白酶抑制剂的取代的2,5-二氨基-3-羟基己烷由通式I表示。（C）2006，JPO和NCIPI

公开(公告)号：JP2011153148A

公开(公告)日：2011-08-11

申请号：JP2011049274

申请日：2011-03-07

Applicant: Abbott Lab ,  アボット・ラボラトリーズAbbott Laboratories

Inventor： GOMTSYAN ARTHUR ,  BAYBURT EROL K ,  LEE CHIH-HUNG ,  KOENIG JOHN R ,  SCHMIDT ROBERT ,  LUKIN KIRILL ,  CHAMBOURNIER GILLES ,  HSU MARGARET ,  LEANNA M ROBERT ,  CINK RUSSEL D

IPC: C07D217/02 ,  A61K31/416 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/472 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/55 ,  A61K31/553 ,  A61P13/02 ,  A61P13/10 ,  A61P25/04 ,  A61P43/00 ,  C07D231/56 ,  C07D401/12 ,  C07D403/12 ,  C07D413/12 ,  C07D451/02 ,  C07D471/08

CPC classification number: C07D403/12 ,  C07D217/02 ,  C07D231/56 ,  C07D401/12

Abstract: PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for treating disorders selected from the group consisting of pain, bladder hyperactivity, urinary incontinence and inflammatory thermal hyperalgesia by inhibiting vanilloid receptor subtype 1 in mammals. SOLUTION: The pharmaceutical composition includes a new compound represented and exemplified by formula (XI) or a pharmaceutically acceptable salt etc., thereof. COPYRIGHT: (C)2011,JPO&INPIT

Abstract translation: 待解决的问题：提供通过抑制哺乳动物中的香草素受体亚型1来提供用于治疗选自疼痛，膀胱多动症，尿失禁和炎症性热痛觉过敏的药物组合物。 解决方案：药物组合物包括由式（XI）表示和示例的新化合物或其药学上可接受的盐等。 版权所有（C）2011，JPO＆INPIT

公开(公告)号：WO9834917A3

公开(公告)日：1999-01-14

申请号：PCT/US9802439

申请日：1998-02-06

Applicant: ABBOTT LAB

Inventor： LEANNA M ROBERT ,  HANNICK STEVEN M ,  RASMUSSEN MICHAEL ,  TIEN JIEN-HEH J ,  BHAGAVATULA LAKSHMI ,  SINGAM PULLA REDDY ,  GATES BRADLEY D ,  KOLACZKOWSKI LAWRENCE ,  PATEL RAMESH R ,  WAYNE GREG ,  LANNOYE GREG ,  ZHANG WEIJIANG ,  TIAN ZHENPING ,  LUKIN KIRILL L ,  NARAYANAN BIKSHANDARKOR A ,  RILEY DAVID A ,  MORTON HOWARD ,  CHANG SOU-JEN

IPC: C12P7/62 ,  A61K31/52 ,  A61P31/12 ,  A61P31/18 ,  A61P31/22 ,  C07C69/16 ,  C07C309/73 ,  C07D473/18 ,  C07D473/40 ,  C07D73/00

CPC classification number: C07D473/18

Abstract: Methods and novel intermediates for the preparation of acyclic nucleoside derivatives of formula (I) where one of R1 and R2 is an amino acid acyl group and the other of R1 and R2 is a -C(O)C3-C21 saturated or monounsaturated, optionally substituted alkyl and R3 is OH or H; or a pharmaceutically acceptable salt thereof.

公开(公告)号：DK1658269T3

公开(公告)日：2009-01-12

申请号：DK04754996

申请日：2004-06-10

Applicant: ABBOTT LAB

Inventor： GOMTSYAN ARTHUR ,  BAYBURT EROL K ,  LEE CHIH-HUNG ,  KOENIG JOHN R ,  SCHMIDT ROBERT ,  LUKIN KIRILL ,  CHAMBOURNIER GILLES ,  HSU MARGARET ,  LEANNA M ROBERT ,  CINK RUSSEL D

IPC: C07D217/02 ,  A61K31/416 ,  A61K31/472 ,  A61P13/10 ,  C07C211/42 ,  C07D231/56 ,  C07D401/12 ,  C07D403/12

Abstract: The present invention discloses novel compounds of general formula (I), or a pharmaceutically acceptable salt thereof (in which X 1 - X 5 , R 5 - R 8b , Z 1 - Z 2 and Ar 1 are defined herein), pharmaceutical compositions including those compounds and a process for making those compounds. The compounds of formula (I) are useful for treating pain, bladder overreactivity, urinary incontinence, inflammatory hyperalgesia by inhibiting the VR1 receptor in mammals.

公开(公告)号：CA2174000C

公开(公告)日：2005-05-24

申请号：CA2174000

申请日：1994-09-26

Applicant: ABBOTT LAB

Inventor： STUK TIMOTHY L ,  KERDESKY FRANCIS A J ,  LIJEWSKI LINDA M ,  NORBECK DANIEL W ,  SCARPETTI DAVID ,  TIEN JIEN-HEH J ,  ALLEN MICHAEL S ,  LANGRIDGE DENTON C ,  MELCHER LAURA ,  RENO DANIEL S ,  SHAM HING LEUNG ,  ZHAO CHEN ,  HAIGHT ANTHONY R ,  LEANNA M ROBERT ,  MORTON HOWARD E ,  ROBBINS TIMOTHY A ,  SOWIN THOMAS J

IPC: C07C213/00 ,  C07C215/28 ,  C07C225/16 ,  C07C227/18 ,  C07C229/36 ,  C07C231/12 ,  C07C233/35 ,  C07C251/40 ,  C07C255/27 ,  C07C255/42 ,  C07C269/06 ,  C07C271/20 ,  C07D209/44 ,  C07D221/14 ,  C07C233/36 ,  C07C217/58 ,  C07C233/78

Abstract: Intermediates and processes are disclosed which are useful for the preparati on of a substantially pure compound of formula (3), wherein R6 and R7 are each hydrogen or R6 and R7 are independently selected from (i), wherein Ra and Rb are independently selected from hydrogen, loweralkyl and phenyl and Rc, Rd a nd Re are independently selected from hydrogen, loweralkyl, trifluoromethyl, alkoxy, halo and phenyl; and (ii) wherein the naphthyl ring is unsubstituted or substituted with one, two or three substituents independently selected fr om loweralkyl, trifluoromethyl, alkoxy and halo; or R6 is as defined above and R7 is R7aOC (O)-wherein R7a is loweralkyl or benzyl; or R6 and R7 taken togethe r with the nitrogen atom to which they are bonded are (a) or (b), wherein Rf, Rg, Rh and Ri are independently selected from hydrogen, loweralkyl, alkoxy, halogen and trifluoromethyl and R8 is hydrogen or -C(O)R" wherein R" is loweralkyl, alkoxy, benzyloxy or phenyl wherein the phenyl ring is unsubstituted or substituted with one, two or three substituents independent ly selected from loweralkyl, trifluoromethyl, alkoxy and halo; or an acid addition salt thereof.

公开(公告)号：AU2004247721A1

公开(公告)日：2004-12-23

申请号：AU2004247721

申请日：2004-06-10

Applicant: ABBOTT LAB

Inventor： HSU MARGARET ,  SCHMIDT ROBERT ,  BAYBURT EROL K ,  LUKIN KIRILL ,  LEANNA M ROBERT ,  LEE CHIH-HUNG ,  CHAMBOURNIER GILLES ,  CINK RUSSEL D ,  GOMTSYAN ARTHUR ,  KOENIG JOHN R

IPC: C07D217/02 ,  A61K31/416 ,  A61K31/472 ,  A61P13/10 ,  C07C211/42 ,  C07D231/56 ,  C07D401/12 ,  C07D403/12

Abstract: The present invention discloses novel compounds of general formula (I), or a pharmaceutically acceptable salt thereof (in which X 1 - X 5 , R 5 - R 8b , Z 1 - Z 2 and Ar 1 are defined herein), pharmaceutical compositions including those compounds and a process for making those compounds. The compounds of formula (I) are useful for treating pain, bladder overreactivity, urinary incontinence, inflammatory hyperalgesia by inhibiting the VR1 receptor in mammals.

公开(公告)号：CA2174000A1

公开(公告)日：1995-04-27

申请号：CA2174000

申请日：1994-09-26

Applicant: ABBOTT LAB

Inventor： STUK TIMOTHY L ,  KERDESKY FRANCIS A J ,  LIJEWSKI LINDA M ,  NORBECK DANIEL W ,  SCARPETTI DAVID ,  TIEN JIEN-HEH J ,  ALLEN MICHAEL S ,  LANGDRIDGE DENTON C ,  MELCHER LAURA ,  RENO DANIEL S ,  SHAM HING LEUNG ,  ZHAO CHEN ,  HAIGHT ANTHONY R ,  LEANNA M ROBERT ,  MORTON HOWARD E ,  ROBBINS TIMOTHY A ,  SOWIN THOMAS J

IPC: C07C213/00 ,  C07C215/28 ,  C07C225/16 ,  C07C227/18 ,  C07C229/36 ,  C07C231/12 ,  C07C233/35 ,  C07C251/40 ,  C07C255/27 ,  C07C255/42 ,  C07C269/06 ,  C07C271/20 ,  C07D209/44 ,  C07D221/14 ,  C07C233/36 ,  C07C217/58 ,  C07C233/78

Abstract: Intermediates and processes are disclosed which are useful for the preparation of a substantially pure compound of formula (3), wherein R6 and R7 are each hydrogen or R6 and R7 are independently selected from (i), wherein Ra and Rb are independently selected from hydrogen, loweralkyl and phenyl and Rc, Rd and Re are independently selected from hydrogen, loweralkyl, trifluoromethyl, alkoxy, halo and phenyl; and (ii) wherein the naphthyl ring is unsubstituted or substituted with one, two or three substituents independently selected from loweralkyl, trifluoromethyl, alkoxy and halo; or R6 is as defined above and R7 is R7aOC (O)-wherein R7a is loweralkyl or benzyl; or R6 and R7 taken together with the nitrogen atom to which they are bonded are (a) or (b), wherein Rf, Rg, Rh and Ri are independently selected from hydrogen, loweralkyl, alkoxy, halogen and trifluoromethyl and R8 is hydrogen or -C(O)R" wherein R" is loweralkyl, alkoxy, benzyloxy or phenyl wherein the phenyl ring is unsubstituted or substituted with one, two or three substituents independently selected from loweralkyl, trifluoromethyl, alkoxy and halo; or an acid addition salt thereof.

公开(公告)号：AU2010257277A1

公开(公告)日：2011-01-13

申请号：AU2010257277

申请日：2010-12-17

Applicant: ABBOTT LAB

Inventor： GOMTSYAN ARTHUR ,  LEE CHIH-HUNG ,  CHAMBOURNIER GILLES ,  KOENIG JOHN R ,  LUKIN KIRILL ,  LEANNA M ROBERT ,  HSU MARGARET ,  SCHMIDT ROBERT ,  CINK RUSSEL D

IPC: A61P13/10 ,  C07D217/02 ,  C07D231/56 ,  C07D401/12 ,  C07D403/12

Abstract: The present invention discloses novel compounds of general formula (I), or a pharmaceutically acceptable salt thereof (in which X 1 - X 5 , R 5 - R 8b , Z 1 - Z 2 and Ar 1 are defined herein), pharmaceutical compositions including those compounds and a process for making those compounds. The compounds of formula (I) are useful for treating pain, bladder overreactivity, urinary incontinence, inflammatory hyperalgesia by inhibiting the VR1 receptor in mammals.

公开(公告)号：DE602004017329D1

公开(公告)日：2008-12-04

申请号：DE602004017329

申请日：2004-06-10

Applicant: ABBOTT LAB

Inventor： GOMTSYAN ARTHUR ,  BAYBURT EROL K ,  LEE CHIH-HUNG ,  KOENIG JOHN R ,  SCHMIDT ROBERT ,  LUKIN KIRILL ,  CHAMBOURNIER GILLES ,  HSU MARGARET ,  LEANNA M ROBERT ,  CINK RUSSEL D

IPC: C07D217/02 ,  A61K31/416 ,  A61K31/472 ,  A61P13/10 ,  C07C211/42 ,  C07D231/56 ,  C07D401/12 ,  C07D403/12

Abstract: The present invention discloses novel compounds of general formula (I), or a pharmaceutically acceptable salt thereof (in which X 1 - X 5 , R 5 - R 8b , Z 1 - Z 2 and Ar 1 are defined herein), pharmaceutical compositions including those compounds and a process for making those compounds. The compounds of formula (I) are useful for treating pain, bladder overreactivity, urinary incontinence, inflammatory hyperalgesia by inhibiting the VR1 receptor in mammals.

公开(公告)号：AT238983T

公开(公告)日：2003-05-15

申请号：AT99101692

申请日：1994-09-26

Applicant: ABBOTT LAB

Inventor： STUK TIMOTHY L ,  KERDESKY FRANCIS A J ,  LIJEWSKI-LINCH LINDA M ,  NORBECK DANIEL W ,  SCARPETTI DAVID ,  TIEN JIEN-HEH J ,  ALLEN MICHAEL S ,  LANGRIDGE DENTON C ,  MELCHER LAURA ,  RENO DANIEL S ,  SHAM HING LEUNG ,  ZHAO CHEN ,  HAIGHT ANTHONY R ,  LEANNA M ROBERT ,  MORTON HOWARD E ,  ROBBINS TIMOTHY A ,  SOWIN THOMAS J

IPC: C07C213/00 ,  C07C215/28 ,  C07C225/16 ,  C07C227/18 ,  C07C229/36 ,  C07C231/12 ,  C07C233/35 ,  C07C251/40 ,  C07C255/27 ,  C07C255/42 ,  C07C269/06 ,  C07C271/20 ,  C07D209/44 ,  C07D221/14

Abstract: Processes are disclosed which are useful for the preparation of a substantially pure compound of formula (3), wherein R6 and R7 are each hydrogen or R6 and R7 are independently selected from (i), wherein Ra and Rb are independently selected from hydrogen, loweralkyl and phenyl and Rc, Rd and Re are independently selected from hydrogen, loweralkyl, trifluoromethyl, alkoxy, halo and phenyl; and (ii) wherein the naphthyl ring is unsubstituted or substituted with one, two or three substituents independently selected from loweralkyl, trifluoromethyl, alkoxy, and halo; or R6 is as defined above and R7 is R7aOC (O)- wherein R7a is loweralkyl or benzyl; or R6 and R7 taken together with the nitrogen atom to which they are bonded are (a) or (b), wherein Rf, Rg, Rh and Ri are independently selected from hydrogen, loweralkyl, alkoxy, halogen, and trifluoromethyl and R8 is hydrogen or -C(O)R'' wherein R'' is loweralkyl, alkoxy, benzyloxy or phenyl wherein the phenyl ring is unsubstituted or substituted with one, two or three substituents independently selected from loweralkyl, trifluoromethyl, alkoxy and halo; or an acid addition salt thereof.